Raymond James Financial Inc. Invests $88,000 in Altimmune, Inc. (NASDAQ:ALT)

Raymond James Financial Inc. acquired a new stake in Altimmune, Inc. (NASDAQ:ALT) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,240 shares of the company’s stock, valued at approximately $88,000.

Other large investors have also recently added to or reduced their stakes in the company. Wells Fargo & Company MN lifted its holdings in Altimmune by 69.3% in the fourth quarter. Wells Fargo & Company MN now owns 215,538 shares of the company’s stock valued at $1,554,000 after acquiring an additional 88,209 shares during the last quarter. SBI Securities Co. Ltd. acquired a new position in Altimmune in the fourth quarter valued at approximately $45,000. Invesco Ltd. lifted its holdings in Altimmune by 679.2% in the fourth quarter. Invesco Ltd. now owns 247,086 shares of the company’s stock valued at $1,781,000 after acquiring an additional 215,375 shares during the last quarter. LPL Financial LLC lifted its holdings in Altimmune by 15.2% in the fourth quarter. LPL Financial LLC now owns 58,173 shares of the company’s stock valued at $419,000 after acquiring an additional 7,693 shares during the last quarter. Finally, Wellington Management Group LLP lifted its holdings in Altimmune by 4.1% in the fourth quarter. Wellington Management Group LLP now owns 205,233 shares of the company’s stock valued at $1,480,000 after acquiring an additional 8,001 shares during the last quarter. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Altimmune Trading Down 4.2%

Shares of NASDAQ ALT opened at $5.76 on Wednesday. Altimmune, Inc. has a twelve month low of $3.55 and a twelve month high of $11.16. The stock has a fifty day simple moving average of $5.10 and a 200-day simple moving average of $6.59. The stock has a market capitalization of $443.60 million, a PE ratio of -3.72 and a beta of 1.13.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.10. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same quarter last year, the company earned ($0.34) EPS. On average, equities analysts predict that Altimmune, Inc. will post -1.35 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently commented on ALT shares. William Blair reiterated a “market perform” rating on shares of Altimmune in a report on Friday, March 14th. HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of Altimmune in a research report on Thursday, April 3rd. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $20.20.

Insiders Place Their Bets

In other Altimmune news, CFO Gregory L. Weaver bought 10,000 shares of the firm’s stock in a transaction dated Thursday, March 13th. The stock was acquired at an average price of $5.20 per share, for a total transaction of $52,000.00. Following the completion of the purchase, the chief financial officer now owns 10,000 shares of the company’s stock, valued at approximately $52,000. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.10% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.